All News

New study may have found a way to prevent the loss of physical strength in type 1 diabetes patients.

Generic abacavir and lamivudine (Epzicom) tablets are indicated for the treatment of HIV-1 infection in combination with other antiretroviral medicines.

Rehydrating freeze-dried cellular components produces useful proteins.

Top news of the day from across the health care landscape.

Enzyme found to promote immune suppression by blocking the activation of anti-tumor T cells.

Stelara is the first biologic approved for Crohn’s disease targeting cytokines that play a key role in inflammatory and immune responses.

Top news of the day from across the healthcare landscape.

The top vaccine candidate for Zika virus is expected to be ready for field testing next year in the event of outbreaks in the United States.

Teva has launched the generic equivalent of abacavir and lamivudine (Epzicom) tablets in the United States.

This article highlights several key therapeutics areas with tenofovir alafenamid that every pharmacist should know.

Improvements to opioid prescribing, increasing the use of naloxone to reverse opioid overdose and expanding the use of medication-assisted treatment (MAT) for opioid-use disorders were among the many suggestions to come out of the Academy of Managed Care Pharmacy (AMCP) Foundation 6th Annual Research Symposium, Balancing Access and Use of Opioid Therapy."

One worry that many pharmacy students have when they get out of school concerns how to tell a physician that a mistake's been made with a medication dose or frequency and then how to explain the right course of action.

Drug resistance to antiretroviral therapy is a persistent and pernicious challenge to successful HIV treatment.

A Connecticut man sentenced to 6 years in prison last year for conspiracy to pass 2 forged prescriptions is now being accused of passing more fraudulent prescriptions successfully and netting more than 1000 tablets of medication.

New research explores the difference between statins and PCSK9 inhibitors.

Spending on specialty drugs for autoimmune conditions now account for 10% of drug expenses.

The Harrison School of Pharmacy started a free training program for assisting Medicare beneficiaries eligible for subsidies.

A nanoparticle delivery system may help manage autoimmune diseases, such as multiple sclerosis, leaving a temporary black mark on patients.

A 7-year study identified genetic pathways hijacked by cancer stem cells to promote tumor growth.

Device shows promise preventing cancer cells from migrating to other organs in the body.

Aetna will offer subsidies for consumers to purchase an Apple Watch.

A small FDA-approved clinical trial is expected to start next month to test the efficacy of a drug for patients who stutter.

Top news of the day from across the health care landscape.

Pharma has had little incentive to develop drugs for diseases such as malaria, which killed more than 400,000 people last year.

Crisaborole topical ointment shows promise in treating atopic dermatitis.

Top news of the day from across the healthcare landscape.

Stelara is the first biologic approved for Crohn’s disease targeting interleukin (IL)-12 and IL-23 cytokines, which play a key role in inflammatory and immune responses.

Oral formulation of methylnaltrexone bromide available for adults with chronic noncancer pain.

Pharmacists immunize populations unlikely to otherwise receive vaccines. However, incompatible data systems obscure evidence of vaccination receipt and increase the risk of repetitive vaccination.

The FDA recently approved Janssen's ustekinumab (Stelara) for the treatment of moderate to severe active Crohn's disease in adults who have failed or were intolerant to treatment with immunomodulators or corticosteroids but never failed treatment with a tumor necrosis factor (TNF) blocker, as well as those who failed or were intolerant to treatment with one or more TNF blockers.